Clinical Trials & Surveys Corp. (C-TASC)
, a clinical trials solutions company, announced it has hired Jose Gallo, Ph.D. as senior director of biometrics consulting. In this position, Dr. Gallo will lead C-TASC’s consulting team as it works with pharmaceutical and biotechnology companies to address all biometric issues associated with clinical trial submissions. This will include providing standard contract research organization (CRO) activities plus support for Phase IV trial work, post submission-related work and the communication of trial results. Additionally, Dr. Gallo will support C-TASC’s current work with government agencies, including the National Institutes of Health (NIH) and the Food and Drug Administration (FDA).
Dr. Gallo has more than 23 years of experience in healthcare technology with over 17 of those years spent in managerial roles. Before joining C-TASC, Dr. Gallo worked as an independent statistical consultant and provided statistical advice as well as advice on issues related to FDA and European Medicines Agency (EMA) submissions. Previously, he was the director of biometrics at Therakos, a Johnson & Johnson company, where he developed and led a biometrics department that supported the clinical research associated with assessing the efficacy and safety of Extracorporeal Photopheresis in various therapeutic areas. Prior to that, he had numerous managerial positions, including vice president of biometrics at Eximias Pharmaceuticals and leadership roles at AstraZeneca LP. Dr. Gallo holds a Ph.D. and master’s degree in statistics from the University of Florida.
For 20 years, C-TASC has specialized in supporting best practices management of clinical trials and studies for government, university and private organizations. The company has grown rapidly in the last three years, nearly doubling its revenue and number of employees since 2007. In that time, it has added professional consultation in all areas of clinical trial management to its offered services, incorporated a proprietary Web-based software system for clinical trials management and developed a relationship with the FDA to convert legacy data into the new standard Study Data Tabulation Model (SDTM) format.
“With his extensive background and biometric expertise, Jose is the ideal person to lead our consulting team as we continue to expand our service offerings for the pharmaceutical and biotechnology industries,” said Dr. Bruce Thompson, president of C-TASC.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.